Here are the S-3 shelf registrations from Kalaris Therapeutics, Inc. (KLRS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow KLRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KLRS filings page.
Kalaris Therapeutics, Inc. is registering up to $350,000,000 of securities on a shelf, including an $100,000,000 program to sell common stock under a sales agreement.
The prospectus covers debt securities, common stock, preferred stock, subscription rights, warrants and units that may be offered "from time to time"; specific terms and distribution methods will be set forth in prospectus supplements. The company has an at-the-market sales agreement with TD Cowen that permits sales of up to $100,000,000 of common stock, with compensation up to 3.0%.
Kalaris Therapeutics, Inc. registers for resale up to 5,000,000 shares of its common stock, consisting of 4,200,000 outstanding shares and 800,000 shares issuable upon exercise of pre-funded warrants. The prospectus covers resales by the selling stockholders; the company will not receive proceeds from resales, although it would receive cash if pre-funded warrants are exercised at an exercise price of $0.0001 per share. The shares were issued in a private placement that generated approximately $50.0 million in gross proceeds at a price of $10.00 per share (and pre-funded warrants at $9.9999), and the registration statement was filed to satisfy registration rights. Shares outstanding were 22,928,303 as of February 28, 2026. The prospectus permits sales on Nasdaq or other methods described under "Plan of Distribution," and notes a Beneficial Ownership Limitation (default 4.99%, adjustable up to 19.99% with notice).